- Home
- PMVP vs BLUE Comparison
PMVP vs BLUE Comparison
Compare PMVP & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- BLUE
- Stock Information
- Founded
- PMVP 2013
- BLUE 1992
- Country
- PMVP United States
- BLUE United States
- Employees
- PMVP N/A
- BLUE N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMVP Health Care
- BLUE Health Care
- Exchange
- PMVP Nasdaq
- BLUE Nasdaq
- Market Cap
- PMVP 85.5M
- BLUE 78.7M
- IPO Year
- PMVP 2020
- BLUE 2013
- Fundamental
- Price
- PMVP $1.61
- BLUE $0.32
- Analyst Decision
- PMVP Strong Buy
- BLUE Hold
- Analyst Count
- PMVP 4
- BLUE 10
- Target Price
- PMVP $5.75
- BLUE $3.03
- AVG Volume (30 Days)
- PMVP 209.2K
- BLUE 5.4M
- Earning Date
- PMVP 11-07-2024
- BLUE 11-14-2024
- Dividend Yield
- PMVP N/A
- BLUE N/A
- EPS Growth
- PMVP N/A
- BLUE N/A
- EPS
- PMVP N/A
- BLUE N/A
- Revenue
- PMVP N/A
- BLUE $53,120,000.00
- Revenue This Year
- PMVP N/A
- BLUE $199.14
- Revenue Next Year
- PMVP N/A
- BLUE $186.62
- P/E Ratio
- PMVP N/A
- BLUE N/A
- Revenue Growth
- PMVP N/A
- BLUE 144.50
- 52 Week Low
- PMVP $1.40
- BLUE $0.32
- 52 Week High
- PMVP $3.47
- BLUE $5.53
- Technical
- Relative Strength Index (RSI)
- PMVP 47.86
- BLUE 23.70
- Support Level
- PMVP $1.59
- BLUE $0.34
- Resistance Level
- PMVP $1.82
- BLUE $0.53
- Average True Range (ATR)
- PMVP 0.07
- BLUE 0.04
- MACD
- PMVP -0.01
- BLUE -0.01
- Stochastic Oscillator
- PMVP 8.70
- BLUE 0.99
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.